A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults

Thomas Werfel, W. Liu, B. Cimoszko et al.|Open Repository and Bibliography (University of Liège)|2016

Cited by 15